SavedAdd your journal

Journals / Turkish Computational and Theoretical Chemistry / 2026 / Volume: 10 Issue: 3

Computational Screening of Ecbolium viride Bioactives as Potential Hepatoprotective Agents Targeting AMPK and PPAR-α

Prabhakar Vengadasamy(SRI SHANMUGHA COLLEGE OF PHARMACY)0009-0001-2579-2273
Selva Bharathi Saravanan(SRI SHANMUGHA COLLEGE OF PHARMACY)0009-0006-2479-7765
Sriram Kalaselvan(SRI SHANMUGHA COLLEGE OF PHARMACY)0000-0001-9759-5386
Arulkumar Rathinavelu(SRI SHANMUGHA COLLEGE OF PHARMACY)0000-0001-6978-0410
Vijayalakshmi Arumugam(Vels Institute of Science, Technology & Advanced Studies, Pallavaram 600117, Chennai, Tamil Nadu, India.)0000-0002-8090-7248
Ramaswamy Ravikumar(SRI SHANMUGHA COLLEGE OF PHARMACY)0000-0002-0364-1925
Sureshkumar Paramasivam(Sri Shanmugha College of Pharmacy(Affiliated to the Tamil Nadu Dr.M.G.R. Medical University), Salem 637304 , Tamil Nadu, India)0000-0002-0661-7314
Pages
—
Publication Date
2026-09-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study goes further by showing these compounds may serve as candidates for further drug development and elucidates their molecular mode of action towards improving liver health.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Liver disorders, which are typically caused by inflammation, oxidative stress and metabolic problems, are becoming a major health problem that is affecting the world at large.
📊
Key Findings & Data:Ecbolium viride, a plant that is commonly utilized in traditional medicine has potential as a natural source of compounds that can assist in defending the liver.
💡
Conclusion & Impact:This study goes further by showing these compounds may serve as candidates for further drug development and elucidates their molecular mode of action towards improving liver health.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ecbolium viride · Hepatoprotective activity · AMPK

Abstract

Liver disorders, which are typically caused by inflammation, oxidative stress and metabolic problems, are becoming a major health problem that is affecting the world at large. Ecbolium viride, a plant that is commonly utilized in traditional medicine has potential as a natural source of compounds that can assist in defending the liver. This study aims to perform a computational analysis of the potential biological activity of these compounds regarding their role in liver health. We centered our study on two crucial enzymes in the body: PPAR which regulates both hepatic fat metabolism and inflammation and AMPK which is a major lipotropic energy sensor. Utilizing molecular docking via AutoDock Vina, we discovered that some of the compounds found in Ecbolium viride strongly bind both PPAR and AMPK, indicating that they can synergistically protect the liver. This study goes further by showing these compounds may serve as candidates for further drug development and elucidates their molecular mode of action towards improving liver health.

🔖

Cite This Article

Vengadasamy, P., Saravanan, S. B., Kalaselvan, S., Rathinavelu, A., Arumugam, V., Ravikumar, R., Paramasivam, S. (2026). Computational Screening of Ecbolium viride Bioactives as Potential Hepatoprotective Agents Targeting AMPK and PPAR-α. Turkish Computational and Theoretical Chemistry, Volume: 10 Issue: 3. https://ajindex.com/articles/1554730

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. M.L. Teng, C.H. Ng, D.Q. Huang, K.E. Chan, D.J. Tan, W.H. Lim, J.D. Yang, E. Tan, M.D. Muthiah, Global incidence and prevalence of nonalcoholic fatty liver disease, Clinical and Molecular Hepatology 29 (2023) S32–S42.
  2. A. Allameh, R. Niayesh-Mehr, A. Aliarab, G. Sebastiani, K. Pantopoulos, Oxidative stress in liver pathophysiology and disease, Antioxidants (Basel) 12 (2023) 1653.
  3. C. Gan, Y. Yuan, H. Shen, et al., Liver diseases: epidemiology, causes, trends and predictions, Signal Transduction and Targeted Therapy 10 (2025) 33.
  4. J. Zou, J. Li, X. Wang, D. Tang, R. Chen, Neuroimmune modulation in liver pathophysiology, Journal of Neuroinflammation 21 (2024) 188.
  5. P.A. Patel-Rodrigues, L. Cundra, D. Alhaqqan, D.T. Gildea, S.M. Woo, J.H. Lewis, Herbal- and dietary-supplement-induced liver injury: a review of the recent literature, Livers 4 (2024) 94–118.
  6. N. Rana, P. Gupta, H. Singh, K. Nagarajan, Role of bioactive compounds, novel drug delivery systems, and polyherbal formulations in the management of rheumatoid arthritis, Combinatorial Chemistry & High Throughput Screening 27 (2024) 353–385.
  7. R. Thilagavathi, S.S. Begum, S.D. Varatharaj, A.K. Balasubramaniam, J.S. George, C. Selvam, Recent insights into the hepatoprotective potential of medicinal plants and plant-derived compounds, Phytotherapy Research 37 (2023) 2102–2118.
  8. A.D. Reegan, M.R. Gandhi, G. Sivaraman, K.F. Cecilia, R. Ravindhran, K. Balakrishna, M.G. Paulraj, S. Ignacimuthu, Bioefficacy of ecbolin A and ecbolin B isolated from Ecbolium viride (Forsk.) Alston on dengue vector Aedes aegypti L. (Diptera: Culicidae), Parasite Epidemiology and Control 1 (2016) 78–84.
  9. V. Prabhakar, R. Arulkumar, S.M. Ali, A. Vijayalakshmi, P.S. Kumar, S.A. Badusha, K. Sriram, K.U. Rathinisha, Mechanistic insights into the anti-urolithiatic potential of Ecbolium viride ethanolic extract: In silico targeting of human glyoxylate reductase hydroxypyruvate reductase and adenine phosphoribosyltransferase, supported by in vitro validation, Trends in Sciences 22 (2025) 9757.
  10. N. Maharajan, K.H. Kim, K.A. Vijayakumar, G.W. Cho, Unlocking Therapeutic Potential: Camphorquinone’s Role in Alleviating Non-Alcoholic Fatty Liver Disease via SIRT1/LKB1/AMPK Pathway Activation, Tissue Engineering and Regenerative Medicine 22 (2025) 129–144.
  11. J. Unagolla, S. Das, R. Flanagan, M. Oehler, J.U. Menon, Targeting chronic liver diseases: molecular markers, drug delivery strategies and future perspectives, International Journal of Pharmaceutics (2024) 124381.
  12. Z. Tang, L. Li, Z. Xia, Exploring Anti-Nonalcoholic Fatty Liver Disease Mechanism of Gardeniae Fructus by Network Pharmacology, Molecular Docking, and Experiment Validation, ACS Omega 7 (2022) 25521–25531.
  13. Y.Y. Qiu, J. Zhang, F.Y. Zeng, Y.Z. Zhu, Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), Pharmacological Research 192 (2023) 106786.
  14. M. Tahri-Joutey, P. Andreoletti, S. Surapureddi, B. Nasser, M. Cherkaoui-Malki, N. Latruffe, Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPARα, International Journal of Molecular Sciences 22 (2021) 8969.
  15. H. Chen, H. Tan, J. Wan, Y. Zeng, J. Wang, H. Wang, X. Lu, PPAR-γ signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets, Pharmacology & Therapeutics 245 (2023) 108391.
  16. Otuokere, “SARS-COV-2 Inhibitors from Azadirachta indica Leaves: Chemical Composition, Molecular Docking and Quantum Chemical Studies”, Turkish Computational and Theoretical Chemistry (TC&TC), vol. 9, no. 2, pp. 8–18, 2025, doi: 10.33435/tcandtc.1502035.
  17. K and S. R. Morais, “Molecular docking and ADMET analysis”, Turkish Computational and Theoretical Chemistry (TC&TC), vol. 9, no. 2, pp. 96–110, 2025, doi: 10.33435/tcandtc.1518215.
  18. T. Huang, J. Sun, S. Zhou, J. Gao, Y. Liu, Identification of direct activator of adenosine monophosphate-activated protein kinase (AMPK) by structure-based virtual screening and molecular docking approach, International Journal of Molecular Sciences 18 (2017) 1408.
  19. S.K. Mandal, B.K. Kumar, P.K. Sharma, S. Murugesan, P.R. Deepa, In silico and in vitro analysis of PPAR–α/γ dual agonists: Comparative evaluation of potential phytochemicals with anti-obesity drug orlistat, Computers in Biology and Medicine 147 (2022) 105796.
  20. J. Zheng, W. Wang, W. Song, Y. Zhang, M. Yao, G. Wang, Z. Huang, F. Li, J. Ren, L. Lin, X. Fan, Investigation of Fructus sophorae extract’s therapeutic mechanism in atrophic vaginitis based on network pharmacology and experimental validation, Frontiers in Pharmacology 16 (2025) 1571976.